epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove carboplatin
    generic
  • remove Zymfentra (infliximab-dyyb)
    infliximab

multicheck MultiCheck Results - 1 Interaction

Smiley face Smiley face

Caution Advised

Smiley face Smiley face carboplatin (generic) + Zymfentra (infliximab-dyyb) (infliximab)

Caution Advised


carboplatin + infliximab

caution advised: combo may incr. risk of serious infection (additive effects)

Additional Considerations

Smiley face Smiley face infliximab in Zymfentra (infliximab-dyyb)

caution advised with narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx with immune modulators may reverse this effect, resulting in altered levels of concomitant drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information